- Our World
- Our Business
- Life at Lupin
- Global Sites
Mumbai, August 08, 2018: Pharma Major Lupin Limited reported its financial performance for the first quarter ending June 30th, 2018. These results were taken on record by the Board of Directors at a meeting held in Mumbai today.
Key Financial & Performance Highlights
Commenting on the results, Mr. Nilesh Gupta, Managing Director, Lupin Limited said, “The first quarter of FY2019 has been subdued, primarily on account of the US and Japan. We have made meaningful progress in building our Complex Generics and Specialty business with the launch of SolosecTM in the US and our successful partnership to commercialize biosimilar Etanercept with Nichi-Iko for Japan and Mylan for Europe and other markets. We remain committed to accelerating new product introductions, evolving our business and delivering on operational and cost efficiencies.”
Consolidated Unaudited Financial Results – Quarter I, FY2019
Amount in Rs. m.
|Particulars||Q1 FY2019||% of sales||Q4 FY2018||% of sales||QoQ Growth %||Q1 FY2018||% of sales||YoY Growth %|
|Other operating income||814||2.2%||553||1.4%||47.2%||628||1.6%||29.6%|
|Total Revenue from operations||38,560||102.2%||40,338||101.4%||-4.4%||38,696||101.6%||-0.4%|
|Gross Profit (Excl. Other operating income)||23,304||61.7%||26,159||65.8%||-10.9%||25,742||67.6%||-9.5%|
|Manufacturing & Other expenses||11,354||30.1%||12,338||31.0%||-8.0%||11,507||30.2%||-1.3%|
|Depreciation & Amortization||2,590||6.9%||2,728||6.9%||-5.1%||2,605||6.8%||-0.6%|
|PBT before exceptional item||3,835||10.2%||5,223||13.1%||-26.6%||4,959||13.0%||-22.7%|
|Exceptional item||14,644 ||36.8%|
|PBT after exceptional item||3,835||10.2%||(9,421)||-23.7%||4,959||13.0%||-22.7%|
|(+) Share of Profit from Joint Controlled entity||7||13||(22)|
|(-) Non-Controlling Interest||3||59||(12)|
|Net Profit after exceptional items||2,028||5.4%||(7,835)||-19.7%||3,581||9.4%||-43.4%|
|Add: Exceptional items||11,421||28.7%|
|Net Profit before exceptional items||2,028||5.4%||3,586||9.0%||-43.4%||3,581||9.4%||-43.4%|
 The Company made impairment provision of Rs. 14,644 m. on certain intangible assets acquired as a part of Gavis group acquisition.
 Deferred tax includes deferred tax assets of Rs. 3,223 m. created on difference between tax and book value of certain intangible assets of Gavis.
Income Statement highlights – Q1 FY2019
Balance Sheet highlights
|Particulars||Q1 FY2019||Q4 FY2018||QoQ growth %||Q1 FY2018||YoY growth %|
Note  – Adjusted for excise duty growth for India business – 30.7%
Note  – Adjusted for excise duty growth for API business – 31.9%
Note  – Adjusted for excise duty growth for company – (0.1%)
Lupin’s North America sales for Q1 FY2019 were Rs. 11,858 m. compared sales of Rs. 14,990 m. during Q4 FY2018 and Rs. 16,018 m. during Q1 FY2018; accounting for 31% of Lupin’s global sales.
Lupin’s India formulation sales grew by 23.6% to Rs. 11,924 m. during Q1 FY2019 as compared to Q4 FY2018 and grew by 30.7% ( adjusted for excise duty ) compared to Q1 FY2018; accounting for 32% of Lupin’s global sales.
Lpin is the 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT June 2018).
Lupin’s APAC sales were at Rs. 6,077 m. during Q1 FY2019 compared to sales of Rs. 6,637 m. during Q4 FY2018 and Rs. 5,989 m. during Q1 FY2018; accounting for 16% of Lupin’s global sales
Lupin’s Japan sales were JPY 8,129 m. during Q1 FY2019 compared to JPY 8,497 m. during Q4 FY2018 and JPY 8,585 m. in Q1 FY2018.
Lupin remains the 6th largest generic player in Japan (IQVIA MAT June 2018).
Lupin’s Philippines sales were PHP 352 m. during Q1 FY2019 compared to PHP 760 m. during Q4 FY2018 and PHP 350 m. during Q1 FY2018.
Europe, Middle-East and Africa (EMEA)
Lupin’s EMEA sales were Rs. 2,760 m for Q1 FY2019 compared to sales of Rs. 3,513 m. during Q4 FY2018 and Rs. 2,259 m. during Q1 FY2018; accounting for 7% of Lupin’s global sales.
Lupin’s South Africa sales were ZAR 261 m. during Q1 FY2019 compared to ZAR 310 m. during Q4 FY2018 and ZAR 209 m. during Q1 FY2018.
Lupin remains the 4th largest generic player in the South African market (IQVIA MAT June 2018).
Lupin’s Germany sales were Euro 7.5 m. during Q1 FY2019 compared to Euro 8.1 m. during Q4 FY2018 and Euro 6.7 m. during Q1 FY2018.
Latin America (LATAM)
Lupin’s LATAM sales were Rs. 1,256 m. during Q1 FY2019 compared to Rs. 1,645 m. during Q4 FY2018 and Rs. 1,269 m. during Q1 FY2018; accounting for 3% of Lupin’s global sales.
Lupin’s Brazil sales were BRL 25 m. during Q1 FY2019 compared to BRL 44 m. during Q4 FY2018 and BRL 36 m. during Q1 FY2018.
Lupin’s Mexico sales were MXN 159 m. during Q1 FY2019 compared to MXN 167 m. during Q4 FY2018 and MXN 149 m. during Q1 FY2018.
Global API sales increased by 27.5% to Rs. 3,581 m. during Q1 FY2019 as compared to Rs. 2,808 m. during Q4 FY2018 and by 28.2% compared to Rs. 2,793 m. during Q1 FY2018 (adjusted for excise duty growth – 31.9%); accounting for 10% of Lupin’s global sales.
Research and Development
Revenue Expenditure on R&D during Q1 FY2019 amounted to Rs. 3,753 m., 9.9% of sales as against Rs. 4,015 m., 10.1% of sales during Q4 FY2018 and Rs. 4,999 m., 13.1% of sales during Q1 FY2018.
Lupin filed 4 ANDA and received 5 approvals from the US FDA during the quarter. Cumulative ANDA filings with the US FDA stood at 402 as of June 30th, 2018, with the company having received 240 approvals to date.
The Company now has 38 First-to-Files (FTF) filings including 16 exclusive FTF opportunities. Cumulative DMF filings stands at 193 as of June 30th, 2018.
The Company received approval for 1 MAA from the European authority during the quarter. Cumulative filings with European authorities now stands at 61 with the company having received 58 approvals to date.
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 8th largest generics pharmaceutical company both in terms of market capitalization (30th June 2018, Bloomberg) and revenues (31st March 2018, Bloomberg LTM) globally. The Company is the 4th largest pharmaceutical player in the US by prescriptions (IQVIA MAT June 2018); 3rd largest Indian pharmaceutical company by global revenues (31st March 2018, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT June 2018).
For the financial year ended 31st March, 2018, Lupin’s Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.
For further information or queries please contact
|Pooja Thakran||Arvind Bothra|
|VP – Corporate communications||Head – Investor Relations|
|Ph: +91-22 6640 2531 / 9811665000||Ph: +91-22 6640 2137|
|Email: email@example.com||Email: firstname.lastname@example.org|